PatientsVille.com Logo

HYPERHIDROSIS and Effexor

PatientsVille

HYPERHIDROSIS Symptoms and Causes

Sweat is a clear, salty liquid produced by glands in your skin. Sweating is how your body cools itself. You sweat mainly under your arms and on your feet and palms. When sweat mixes with bacteria on your skin, it can cause a smell. Bathing regularly and using antiperspirants or deodorants can help control the odor.

Sweating a lot is normal when it is hot or when you exercise, are anxious, or have a fever. It also happens during menopause. If you often sweat too much, it's called Hyperhidrosis. Causes include thyroid or nervous system disorders, low blood sugar, or another health problem.

Sweating too little, anhidrosis, can be life-threatening because your body can overheat. Causes of anhidrosis include dehydration, burns, and some skin and nerve disorders.

Check out the latest treatments for HYPERHIDROSIS

HYPERHIDROSIS treatment research studies

Effexor clinical trials, surveys and public health registries


Find Drug Side Effect reports



Effexor Side Effects

Dizziness (758)
Nausea (642)
Anxiety (625)
Depression (552)
Feeling Abnormal (546)
Headache (543)
Suicidal Ideation (501)
Condition Aggravated (471)
Paraesthesia (420)
Insomnia (400)
Malaise (400)
Fatigue (339)
Crying (334)
Hyperhidrosis (312)
Confusional State (308)
Agitation (292)
Tremor (286)
Diarrhoea (284)
Asthenia (279)
Convulsion (276)
Completed Suicide (222)
Hypertension (221)
Fall (219)
Disturbance In Attention (207)
Vomiting (204)
Aggression (201)
Blood Pressure Increased (194)
Anger (193)
Withdrawal Syndrome (183)
Somnolence (180)
Pain (177)
Suicide Attempt (175)
Weight Increased (163)
Abnormal Behaviour (151)
Dyspnoea (150)
Amnesia (150)
Intentional Overdose (136)
Irritability (135)
Abnormal Dreams (123)
Tinnitus (118)
Activities Of Daily Living Impaired (117)
Serotonin Syndrome (115)
Loss Of Consciousness (111)
Panic Attack (111)
Arthralgia (110)
Nightmare (109)
Disorientation (108)
Off Label Use (106)
Overdose (106)
Emotional Disorder (105)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

10 years on effexor, weight gain of 20 lbs last 5 years when increased to 300mg., no change in cal or exercise, since getting older realized needed fewre calories so tried to reduce like always could wirhWW and exercise, no success, couldn'

Effexor & Pristiq is poison - I would know, I started taking it at 16 yrs old, instead of counselling I was given Effexor by a 'psychiatrist drug dealer' I was never offered counselling. I spent of $25,000 on this medication in my lifetime. D

Effexor raised my blood presure alot ,I had extreme painful headaches,rash that started on my face which was horrible,then spread to my chest,my neck was beat red I itched so badly.I think docotrs need to be more educated on this med before giveing i

Effexor was horrible for me...as soon as I started it I started having panic attacks worse than ever (supposed to help them) scary bad dreams, waking up in a sweat and not knowing who I was, then depression. The first day I expeirenced the panic atta

Ever since i've been prescribed effexor, my systolic bp measurement is high. is there a correlation between the two.

Had effexor yesterday 75 mg not again nusea,blurred vision and today the worst longest headache I have ever had,GP didn't even check my BP before prescription.I am recovering from a fractured skull think I will deal with my depression without drugs

Headaches BAD and very sleepy and increased anxiety

Hi.. I have been on effexor. I stopped 'cold turkey'. I know this is wrong. I have gained 25 pounds in the past year. I have increasingly became more depressed. I can't sleep. I have strong thoughts of wanting to die. I don't want to kill myself, but

I agree, this has been a horrile drug experience for me as well .. Effexor should be OFF the market !!!! 46 yr old female, Baltimore MD USA

I am taking 300mg of effexor and I believe is it causing dysuria. Could this be correct?

I have experienced a mild form of hyperhidrosis since I was in middle school. Through highschool, I would tape paper towels under my arms, wear tanktops, put on an insane amount of deodorant and put baby powder on three times a day.&nbs

HYPERHIDROSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Botox (onabotulinumtoxinA);   Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB);   Drug: NaCl (placebo)
Outcome Measures: DLQI (Dermatology Life Quality Index);   AE (Adverse Events);   Gravimetry;   HDSS (Hyperhidrosis Disease Severity Scale);   Health outcome (EQ-5D);   LSAS-SR (Liebowitz Social Anxiety Scale-Self Report);   MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report);   Global Assessment of Therapy
2 Not yet recruiting Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Condition: Primary Hyperidrosis
Interventions: Drug: Oxybutynin;   Drug: Placebo
Outcome Measures: Oxybutynin Chloride efficacy;   Perception of improvement;   Evaluate therapeutic safety;   Quality of life;   Time of subject response;   Duration of response;   Evaluation between quality of life and groups
3 Recruiting Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Device: Ulthera System Treatment
Outcome Measures: Reduction in the number of sweat glands from baseline to 90-days post-treatment.;   Reduction in spontaneous axillary sweat production assessed by gravimetric method at 90-days post treatment;   HDSS score reduction;   Starch iodine test
4 Recruiting Tx Axillary Hyperhidrosis 1210nm Diode Laser
Condition: Axillary Hyperhidrosis
Intervention: Device: 1210nm Diode Laser treatments
Outcome Measures: subjective global assessment questionnaire;   gravimetric analysis;   modified starch-iodine test
5 Recruiting Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Dose 1 of DRM04B;   Drug: Dose 2 of DRM04B;   Drug: Dose 1 of DRM04;   Drug: Dose 2 of DRM04;   Other: Vehicle
Outcome Measures: Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4;   Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 6;   Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6
6 Recruiting A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Drug: BBI-4000
Outcome Measures: Percent change in the gravimetrically measured sweat production from baseline;   Absolute change in the gravimetrically measured sweat production from baseline;   Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.;   Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline
7 Recruiting Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
Condition: Hyperhidrosis
Intervention: Drug: [14C]Umeclidinium 18.5 mg
Outcome Measures: PK Assessment (Cmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (tmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (AUC) for [14C] umeclidinium and total radioactivity;   PK Assessment (t1/2) for [14C] umeclidinium and total radioactivity;   Compartmental modeling of absorption rate for [14C] umeclidinium;   Compartmental modeling of elimination rate for [14C] umeclidinium;   Determine the amount of Umeclidinium absorbed in the skin;   Safety Assessment for AEs;   Safety Assessment for ECGs, and telemetry;   Safety Assessment for hematology laboratory parameters;   Safety Assessment for measurement of blood pressure;   Number of subjects with application site skin irritation;   Safety Assessment for clinical chemistry laboratory parameters;   Safety Assessment for measurement of pulse rate
8 Recruiting Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
Conditions: Hyperhydrosis;   Depression
Intervention: Drug: Glycopyrrolate
Outcome Measures: Clinical Global Impression- Improvement scores;   change in mean of patient rated severity of sweating for each week, and change in mean skin conductance for each week
9 Recruiting Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Condition: Menopausal Hot Flushes
Intervention: Drug: Sage extract, 3400 mg , DER 1:17
Outcome Measures: Change from Baseline Hyperhidrosis Disease Severity Scale;   Change from Baseline Menopause Rating Scale / MRS;   Change from Baseline Modified Dem Tect
10 Recruiting Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle
Condition: Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc.
Intervention: Procedure: lumbar sympathetic ganglion block
Outcome Measures: temperature change;   muscle or vessel shadow
11 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
12 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
Outcome Measure:
13 Not yet recruiting Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
Condition: Complex Regional Pain Syndrome Type I of the Upper Limb
Intervention: Procedure: unilateral single-port VATS sympathicotomy
Outcome Measures: Change in perceived pain measured in Visual Analogue Scale;   Change in function in extremity